{"id":"gentamicin","rwe":[{"pmid":"41905318","year":"2026","title":"Antibiotic use among beef cattle farmers in feedlots in Querétaro, Mexico.","finding":"","journal":"Revista Argentina de microbiologia","studyType":"Clinical Study"},{"pmid":"41905081","year":"2026","title":"A baseline assessment of Enterococcus in low-contamination surface waters and their antibiotic resistance.","finding":"","journal":"Marine pollution bulletin","studyType":"Clinical Study"},{"pmid":"41904538","year":"2026","title":"TNF-α impairs the stria vascularis by inducing pericyte apoptosis via the NF-κB pathway in gentamicin-induced hearing loss.","finding":"","journal":"Journal of neuroinflammation","studyType":"Clinical Study"},{"pmid":"41904345","year":"2026","title":"UV-spectrometric study of antibiotic long-term release by different osteoplastic materials used in dentistry.","finding":"","journal":"The Saudi dental journal","studyType":"Clinical Study"},{"pmid":"41903513","year":"2026","title":"Predictors, aetiology and outcome of early-onset neonatal bloodstream infection: a case-control study in a tertiary hospital in South Africa.","finding":"","journal":"Journal of tropical pediatrics","studyType":"Clinical Study"}],"_fda":{"id":"09cf496c-8177-ebb7-e063-6394a90a745a","set_id":"09cf88af-59da-f147-e063-6294a90aac99","openfda":{"upc":["0363323010010"],"unii":["8X7386QRLV"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["313996"],"spl_id":["09cf496c-8177-ebb7-e063-6394a90a745a"],"brand_name":["Gentamicin"],"spl_set_id":["09cf88af-59da-f147-e063-6294a90aac99"],"package_ndc":["71872-7311-1"],"product_ndc":["71872-7311"],"generic_name":["GENTAMICIN SULFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["GENTAMICIN SULFATE"],"manufacturer_name":["Medical Purchasing Solutions, LLC"],"application_number":["ANDA062366"],"original_packager_product_ndc":["63323-010"]},"version":"1","warnings":["WARNINGS: (See BOXED WARNINGS .) Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Serious side effects to mother, fetus or newborn have not been reported in the treatment of pregnant women with other aminoglycosides. Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate. It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus."],"overdosage":["OVERDOSAGE: In the event of overdosage or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably lower by peritoneal dialysis than it is by hemodialysis."],"description":["DESCRIPTION: Gentamicin sulfate, a water-soluble antibiotic of the aminoglycoside group, is derived by the growth of Micromonospora purpurea , an actinomycete. It has the following structural formula. Gentamicin injection is a sterile, nonpyrogenic aqueous solution for parenteral administration. Each mL contains: Gentamicin sulfate equivalent to 40 mg gentamicin, methylparaben 1.8 mg and propylparaben 0.2 mg as preservatives, sodium metabisulfite 3.2 mg and edetate disodium 0.1 mg, Water for Injection q.s. Sodium hydroxide and/or sulfuric acid may have been added for pH adjustment. Structure"],"precautions":["PRECAUTIONS: General Prescribing Gentamicin Injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Neurotoxic and nephrotoxic antibiotics may be almost completely absorbed from body surfaces (except urinary bladder) after local irrigation and after topical application during surgical procedures. The potential toxic effects of antibiotics administered in this fashion (neuromuscular blockage, respiratory paralysis, oto- and nephrotoxicity) should be considered (see BOXED WARNINGS ). Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. Neuromuscular blockade and respiratory paralysis have been reported in the cat receiving high doses (40 mg/kg) of gentamicin. The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse it. Aminoglycosides should be used with caution in patients with neuromuscular disorders, such as myasthenia gravis or parkinsonism, since these drugs may aggravate muscle weakness because of their potential curare-like effects on the neuromuscular junction. During or following gentamicin therapy, paresthesias, tetany, positive Chvostek and Trousseau signs and mental confusion have been described in patients with hypomagnesemia, hypocalcemia and hypokalemia. When this has occurred in infants, tetany and muscle weakness has been described. Both adults and infants required corrective electrolyte therapy. Elderly patients may have reduced renal function which may not be evident in the results of routine screening tests such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function during treatment with gentamicin, as with other aminoglycosides, is particularly important in such patients. A Fanconi-like syndrome, with aminoaciduria and metabolic acidosis has been reported in some adults and infants being given gentamicin injections. Cross-allergenicity among aminoglycosides has been demonstrated. Patients should be well hydrated during treatment. Although the in vitro mixing of gentamicin and carbenicillin results in a rapid and significant inactivation of gentamicin, this interaction has not been demonstrated in patients with normal renal function who received both drugs by different routes of administration. A reduction in gentamicin serum half-life has been reported in patients with severe renal impairment receiving carbenicillin concomitantly with gentamicin. Treatment with gentamicin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy is indicated. See BOXED WARNINGS regarding concurrent use of potent diuretics and regarding concurrent and/or sequential use of other neurotoxic and/or for other essential information. Information for Patients Patients should be counseled that antibacterial drugs including Gentamicin Injection, USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Gentamicin Injection, USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Gentamicin Injection, USP or other antibacterial drugs in the future. Pregnancy Category D See WARNINGS section.","General Prescribing Gentamicin Injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Neurotoxic and nephrotoxic antibiotics may be almost completely absorbed from body surfaces (except urinary bladder) after local irrigation and after topical application during surgical procedures. The potential toxic effects of antibiotics administered in this fashion (neuromuscular blockage, respiratory paralysis, oto- and nephrotoxicity) should be considered (see BOXED WARNINGS ). Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. Neuromuscular blockade and respiratory paralysis have been reported in the cat receiving high doses (40 mg/kg) of gentamicin. The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse it. Aminoglycosides should be used with caution in patients with neuromuscular disorders, such as myasthenia gravis or parkinsonism, since these drugs may aggravate muscle weakness because of their potential curare-like effects on the neuromuscular junction. During or following gentamicin therapy, paresthesias, tetany, positive Chvostek and Trousseau signs and mental confusion have been described in patients with hypomagnesemia, hypocalcemia and hypokalemia. When this has occurred in infants, tetany and muscle weakness has been described. Both adults and infants required corrective electrolyte therapy. Elderly patients may have reduced renal function which may not be evident in the results of routine screening tests such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function during treatment with gentamicin, as with other aminoglycosides, is particularly important in such patients. A Fanconi-like syndrome, with aminoaciduria and metabolic acidosis has been reported in some adults and infants being given gentamicin injections. Cross-allergenicity among aminoglycosides has been demonstrated. Patients should be well hydrated during treatment. Although the in vitro mixing of gentamicin and carbenicillin results in a rapid and significant inactivation of gentamicin, this interaction has not been demonstrated in patients with normal renal function who received both drugs by different routes of administration. A reduction in gentamicin serum half-life has been reported in patients with severe renal impairment receiving carbenicillin concomitantly with gentamicin. Treatment with gentamicin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy is indicated. See BOXED WARNINGS regarding concurrent use of potent diuretics and regarding concurrent and/or sequential use of other neurotoxic and/or for other essential information.","Information for Patients Patients should be counseled that antibacterial drugs including Gentamicin Injection, USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Gentamicin Injection, USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Gentamicin Injection, USP or other antibacterial drugs in the future.","Pregnancy Category D See WARNINGS section."],"how_supplied":["HOW SUPPLIED: Gentamicin Injection, USP, containing gentamicin 40 mg per mL is supplied as follows: Product Code Unit of Sale Strength Each 1002 NDC 63323-010-02 Unit of 25 80 mg per 2 mL (40 mg per mL) NDC 63323-010-01 2 mL Multiple Dose Vial 1020 NDC 63323-010-20 Unit of 25 800 mg per 20 mL (40 mg per mL) NDC 63323-010-03 20 mL Multiple Dose Vial Also available, Gentamicin Injection (Pediatric), 20 mg per 2 mL (10 mg per mL), supplied in 2 mL (20 mg) vials in packages of 25. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. The container closure is not made with natural rubber latex."],"boxed_warning":["BOXED WARNINGS Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, gentamicin injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage of prolonged therapy. Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with pre-existing renal damage and in patients with normal renal function treated with higher doses and/or for longer periods than recommended. Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions. Renal and eighth cranial nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Urine should be examined for decreased specific gravity, increased excretion of protein and the presence of cells or casts. Blood urea nitrogen (BUN), serum creatinine or creatinine clearance should be determined periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions changes in renal and eighth cranial nerve function may not become manifest until soon after completion of therapy. Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, dosage should be adjusted so that levels above 2 mcg/mL are avoided. Excessive peak and/or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity. In the event of overdosage or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably lower by peritoneal dialysis than it is by hemodialysis. In the newborn infant, exchange transfusions may also be considered. Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin and viomycin, should be avoided. Other factors which may increase patient risk of toxicity are advanced age and dehydration. The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue. Aminoglycosides can cause fetal harm when administered to a pregnant woman (see WARNINGS section)."],"effective_time":"20231110","adverse_reactions":["ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported. They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended. Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy. Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible. Hearing loss is usually manifested initially by diminution of high-tone acuity. Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs. Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported. NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended. Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid reactions, fever and headache; nausea, vomiting, increased salivation and stomatitis; purpura, pseudotumor cerebri, acute organic brain syndrome, pulmonary fibrosis, alopecia, joint pain, transient hepatomegaly and splenomegaly. Laboratory abnormalities possibly related to gentamicin include: increased levels of serum transaminase (SGOT, SGPT), serum LDH and bilirubin; decreased serum calcium, magnesium, sodium and potassium; anemia, leukopenia, granulocytopenia, transient agranulocytosis, eosinophilia, increased and decreased reticulocyte counts and thrombocytopenia. While clinical laboratory test abnormalities may be isolated findings, they may also be associated with clinically related signs and symptoms. For example, tetany and muscle weakness may be associated with hypomagnesemia, hypocalcemia and hypokalemia. While the local tolerance of gentamicin sulfate is generally excellent, there has been an occasional report of pain at the injection site. Subcutaneous atrophy or fat necrosis suggesting local irritation has been reported rarely.","Nephrotoxicity Adverse renal effects, as demonstrated by the presence of casts, cells or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported. They occur more frequently in patients with a history of renal impairment (especially if dialysis is required) and in patients treated for longer periods or with larger doses than recommended.","Neurotoxicity Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if hemodialysis is required) and in patients on high doses and/or prolonged therapy. Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and also hearing loss, which, as with the other aminoglycosides, may be irreversible. Hearing loss is usually manifested initially by diminution of high-tone acuity. Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs. Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome have been reported. NOTE: The risk of toxic reactions is low in patients with normal renal function who did not receive gentamicin sulfate at higher doses or for longer periods of time than recommended. Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss and hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid reactions, fever and headache; nausea, vomiting, increased salivation and stomatitis; purpura, pseudotumor cerebri, acute organic brain syndrome, pulmonary fibrosis, alopecia, joint pain, transient hepatomegaly and splenomegaly. Laboratory abnormalities possibly related to gentamicin include: increased levels of serum transaminase (SGOT, SGPT), serum LDH and bilirubin; decreased serum calcium, magnesium, sodium and potassium; anemia, leukopenia, granulocytopenia, transient agranulocytosis, eosinophilia, increased and decreased reticulocyte counts and thrombocytopenia. While clinical laboratory test abnormalities may be isolated findings, they may also be associated with clinically related signs and symptoms. For example, tetany and muscle weakness may be associated with hypomagnesemia, hypocalcemia and hypokalemia. While the local tolerance of gentamicin sulfate is generally excellent, there has been an occasional report of pain at the injection site. Subcutaneous atrophy or fat necrosis suggesting local irritation has been reported rarely."],"contraindications":["CONTRAINDICATIONS: Hypersensitivity to gentamicin is a contraindication to its use. A history of hypersensitivity or serious toxic reactions to other aminoglycosides may contraindicate use of gentamicin because of the known cross-sensitivity of patients to drugs in this class."],"how_supplied_table":["
Product CodeUnit of Sale StrengthEach
1002NDC 63323-010-02 Unit of 2580 mg per 2 mL (40 mg per mL) NDC 63323-010-01 2 mL Multiple Dose Vial
1020NDC 63323-010-20 Unit of 25800 mg per 20 mL (40 mg per mL) NDC 63323-010-03 20 mL Multiple Dose Vial
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY: After intramuscular (IM) administration of gentamicin sulfate, peak serum concentrations usually occur between 30 and 60 minutes and serum levels are measurable for six to eight hours. When gentamicin is administered by intravenous (IV) infusion over a two-hour period, the serum concentrations are similar to those obtained by IM administration. In patients with normal renal function, peak serum concentrations of gentamicin (mcg/mL) are usually up to four times the single IM dose (mg/kg); for example, a 1 mg/kg injection in adults may be expected to result in a peak serum concentration up to 4 mcg/mL; a 1.5 mg/kg dose may produce levels up to 6 mcg/mL. While some variation is to be expected due to a number of variables such as age, body temperature, surface area and physiologic differences, the individual patient given the same dose tends to have similar levels in repeated determinations. Gentamicin administered at 1 mg/kg every eight hours for the usual 7 to 10 day treatment period to patients with normal renal function does not accumulate in the serum. Gentamicin, like all aminoglycosides, may accumulate in the serum and tissues of patients treated with higher doses and/or for prolonged periods, particularly in the presence of impaired renal function. In adult patients, treatment with gentamicin dosages of 4 mg/kg/day or higher for 7 to 10 days may result in a slight, progressive rise in both peak and trough concentrations. In patients with impaired renal function, gentamicin is cleared from the body more slowly than in patients with normal renal function. The more severe the impairment, the slower the clearance. (Dosage must be adjusted.) Since gentamicin is distributed in extra-cellular fluid, peak serum concentrations may be lower than usual in adult patients who have a large volume of this fluid. Serum concentrations of gentamicin in febrile patients may be lower than those in afebrile patients given the same dose. When body temperature returns to normal, serum concentrations of the drug may rise. Febrile and anemic states may be associated with a shorter than usual serum half-life. (Dosage adjustment is usually not necessary.) In severely burned patients, the half-life may be significantly decreased and resulting serum concentrations may be lower than anticipated from the mg/kg dose. Protein binding studies have indicated that the degree of gentamicin binding is low; depending upon the methods used for testing, this may be between 0 and 30%. After initial administration to patients with normal renal function, generally 70% or more of the gentamicin dose is recoverable in the urine in 24 hours; concentrations in urine above 100 mcg/mL may be achieved. Little, if any, metabolic transformation occurs; the drug is excreted principally by glomerular filtration. After several days of treatment, the amount of gentamicin excreted in the urine approaches the daily dose administered. As with other aminoglycosides, a small amount of the gentamicin dose may be retained in the tissues, especially in the kidneys. Minute quantities of aminoglycosides have been detected in the urine weeks after drug administration was discontinued. Renal clearance of gentamicin is similar to that of endogenous creatinine. In patients with marked impairment of renal function, there is a decrease in the concentration of aminoglycosides in urine and in their penetration into defective renal parenchyma. This decreased drug excretion, together with the potential nephrotoxicity of aminoglycosides, should be considered when treating such patients who have urinary tract infections. Probenecid does not affect renal tubular transport of gentamicin. The endogenous creatinine clearance rate and the serum creatinine level have a high correlation with the half-life of gentamicin in serum. Results of these tests may serve as guides for adjusting dosage in patients with renal impairment (see DOSAGE AND ADMINISTRATION ). Following parenteral administration, gentamicin can be detected in serum, lymph, tissues, sputum and in pleural, synovial and peritoneal fluids. Concentrations in renal cortex sometimes may be eight times higher than the usual serum levels. Concentrations in bile, in general, have been low and have suggested minimal biliary excretion. Gentamicin crosses the peritoneal as well as the placental membranes. Since aminoglycosides diffuse poorly into the subarachnoid space after parenteral administration, concentrations of gentamicin in cerebrospinal fluid are often low and dependent upon dose, rate of penetration and degree of meningeal inflammation. There is minimal penetration of gentamicin into ocular tissues following IM or IV administration. Microbiology Mechanism of Action Gentamicin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria. Mechanism of Resistance Bacterial resistance to gentamicin is generally developed slowly. Bacteria resistant to one aminoglycoside may be resistant to one or more other aminoglycosides. The following bacteria are usually resistant to the aminoglycosides, including gentamicin: most streptococcal species (including Streptococcus pneumoniae and the Group D streptococci), most enterococcal species (including Enterococcus faecalis , E. faecium , and E. durans ), and anaerobic organisms, such as Bacteroides species and Clostridium species. Aminoglycosides are known to be not effective against Salmonella and Shigella species in patients. Therefore, in vitro susceptibility test results should not be reported. Interactions with Other Antimicrobials In vitro studies show that an aminoglycoside combined with an antibiotic that interferes with cell wall synthesis may act synergistically against some enterococcal strains. The combination of gentamicin and penicillin G has a synergistic bactericidal effect against strains of Enterococcus faecalis , E. faecium and E. durans . An enhanced killing effect against many of these strains has also been shown in vitro with combinations of gentamicin and ampicillin, carbenicillin, nafcillin or oxacillin. The combined effect of gentamicin and carbenicillin is synergistic for many strains of Pseudomonas aeruginosa . In vitro synergism against other Gram-negative organisms has been shown with combinations of gentamicin and cephalosporins. Gentamicin may be active against clinical isolates of bacteria resistant to other aminoglycosides. Antibacterial Activity Gentamicin has been shown to be active against most of the following bacteria, both in vitro and in clinical infections (see INDICATIONS AND USAGE ). Gram-Positive Bacteria Staphylococcus species Gram-Negative Bacteria Citrobacter species Enterobacter species Escherichia coli Klebsiella species Proteus species Serratia species Pseudomonas aeruginosa Susceptibility Test Methods When available, the clinical microbiology laboratory should provide cumulative results of the in vitro susceptibility tests for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug for treatment. Dilution Technique Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method. 1, 3 Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of gentamicin powder. The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Technique Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. The standardized procedure requires the use of standardized inoculum concentrations and paper disks impregnated with 10 mcg of gentamicin. 2, 3 The disk diffusion values should be interpreted according to the criteria provided in Table 1. Table 1: Susceptibility Interpretive Criteria for Gentamicin Susceptibility Interpretive Criteria Pathogen Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm) (S) (I) (R) (S) (I) (R) Enterobacteriaceae a ≤4 8 ≥16 ≥15 13 to 14 ≤12 Pseudomonas aeruginosa ≤4 8 ≥16 ≥15 13 to 14 ≤12 Staphylococcus Species b ≤4 8 ≥16 ≥15 13 to 14 ≤12 S = Susceptible, I = Intermediate, R = Resistant a For Salmonella and Shigella spp., aminoglycosides may appear active in vitro but are not effective clinically; the results should not be reported as susceptible b For staphylococci that test susceptible, aminoglycosides are used only in combination with other active agents that test susceptible A report of Susceptible (S) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration usually achievable at the infection site necessary to inhibit growth of the pathogen. A report of Intermediate (I) indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. 1, 2, 3 Standard gentamicin powder should provide the following range of MIC values provided in Table 2. For the diffusion technique using the 10-mcg gentamicin disk the criteria provided in Table 2 should be achieved. Table 2: Acceptable Quality Control Ranges for Gentamicin Quality Control Organism Minimum Inhibitory Concentrations (mcg/mL) Zone Diameter (mm) Escherichia coli ATCC 25922 0.25 to 1 19 to 26 Pseudomonas aeruginosa ATCC 27853 0.5 to 2 17 to 23 Staphylococcus aureus ATCC 25923 Not Applicable 19 to 27 Staphylococcus aureus ATCC 29213 0.12 to 1 Not Applicable Enterococcus faecalis ATCC 29212 4 to 16 Not Applicable Note: For control organisms for gentamicin high-level aminoglycoside screen tests for enterococci, see Table 3I 3","Microbiology Mechanism of Action Gentamicin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria. Mechanism of Resistance Bacterial resistance to gentamicin is generally developed slowly. Bacteria resistant to one aminoglycoside may be resistant to one or more other aminoglycosides. The following bacteria are usually resistant to the aminoglycosides, including gentamicin: most streptococcal species (including Streptococcus pneumoniae and the Group D streptococci), most enterococcal species (including Enterococcus faecalis , E. faecium , and E. durans ), and anaerobic organisms, such as Bacteroides species and Clostridium species. Aminoglycosides are known to be not effective against Salmonella and Shigella species in patients. Therefore, in vitro susceptibility test results should not be reported. Interactions with Other Antimicrobials In vitro studies show that an aminoglycoside combined with an antibiotic that interferes with cell wall synthesis may act synergistically against some enterococcal strains. The combination of gentamicin and penicillin G has a synergistic bactericidal effect against strains of Enterococcus faecalis , E. faecium and E. durans . An enhanced killing effect against many of these strains has also been shown in vitro with combinations of gentamicin and ampicillin, carbenicillin, nafcillin or oxacillin. The combined effect of gentamicin and carbenicillin is synergistic for many strains of Pseudomonas aeruginosa . In vitro synergism against other Gram-negative organisms has been shown with combinations of gentamicin and cephalosporins. Gentamicin may be active against clinical isolates of bacteria resistant to other aminoglycosides. Antibacterial Activity Gentamicin has been shown to be active against most of the following bacteria, both in vitro and in clinical infections (see INDICATIONS AND USAGE ). Gram-Positive Bacteria Staphylococcus species Gram-Negative Bacteria Citrobacter species Enterobacter species Escherichia coli Klebsiella species Proteus species Serratia species Pseudomonas aeruginosa","Susceptibility Test Methods When available, the clinical microbiology laboratory should provide cumulative results of the in vitro susceptibility tests for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug for treatment. Dilution Technique Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method. 1, 3 Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of gentamicin powder. The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Technique Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. The standardized procedure requires the use of standardized inoculum concentrations and paper disks impregnated with 10 mcg of gentamicin. 2, 3 The disk diffusion values should be interpreted according to the criteria provided in Table 1. Table 1: Susceptibility Interpretive Criteria for Gentamicin Susceptibility Interpretive Criteria Pathogen Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm) (S) (I) (R) (S) (I) (R) Enterobacteriaceae a ≤4 8 ≥16 ≥15 13 to 14 ≤12 Pseudomonas aeruginosa ≤4 8 ≥16 ≥15 13 to 14 ≤12 Staphylococcus Species b ≤4 8 ≥16 ≥15 13 to 14 ≤12 S = Susceptible, I = Intermediate, R = Resistant a For Salmonella and Shigella spp., aminoglycosides may appear active in vitro but are not effective clinically; the results should not be reported as susceptible b For staphylococci that test susceptible, aminoglycosides are used only in combination with other active agents that test susceptible A report of Susceptible (S) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration usually achievable at the infection site necessary to inhibit growth of the pathogen. A report of Intermediate (I) indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. 1, 2, 3 Standard gentamicin powder should provide the following range of MIC values provided in Table 2. For the diffusion technique using the 10-mcg gentamicin disk the criteria provided in Table 2 should be achieved. Table 2: Acceptable Quality Control Ranges for Gentamicin Quality Control Organism Minimum Inhibitory Concentrations (mcg/mL) Zone Diameter (mm) Escherichia coli ATCC 25922 0.25 to 1 19 to 26 Pseudomonas aeruginosa ATCC 27853 0.5 to 2 17 to 23 Staphylococcus aureus ATCC 25923 Not Applicable 19 to 27 Staphylococcus aureus ATCC 29213 0.12 to 1 Not Applicable Enterococcus faecalis ATCC 29212 4 to 16 Not Applicable Note: For control organisms for gentamicin high-level aminoglycoside screen tests for enterococci, see Table 3I 3"],"indications_and_usage":["INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important additional concepts contained in the BOXED WARNINGS . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for treatment of endocarditis caused by group D streptococci. Gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin injection may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin."],"spl_unclassified_section":["Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.","REFERENCES: Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Tenth Edition . CLSI document M07-A10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition . CLSI document M02-A12, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement. CLSI document M100-S25, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.","Lake Zurich, IL 60047 www.fresenius-kabi.com/us 45855J Revised: October 2019 Fresenius Kabi Logo"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Gentamicin injection may be given IM or IV. The patient’s pretreatment body weight should be obtained for calculation of correct dosage. The dosage of aminoglycosides in obese patients should be based on an estimate of the lean body mass. It is desirable to limit the duration of treatment with aminoglycosides to short term. PATIENTS WITH NORMAL RENAL FUNCTION Adults The recommended dosage of gentamicin injection for patients with serious infections and normal renal function is 3 mg/kg/day, administered in three equal doses every eight hours (Table 3) . For patients with life-threatening infections, dosages up to 5 mg/kg/day may be administered in three or four equal doses. This dosage should be reduced to 3 mg/kg/day as soon as clinically indicated (Table 3) . It is desirable to measure both peak and trough serum concentrations of gentamicin to determine the adequacy and safety of the dosage. When such measurements are feasible, they should be carried out periodically during therapy to assure adequate but not excessive drug levels. For example, the peak concentration (at 30 to 60 minutes after IM injection) is expected to be in the range of 4 to 6 mcg/mL. When monitoring peak concentrations after IM or IV administration, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring trough concentrations (just prior to the next dose), dosage should be adjusted so that levels above 2 mcg/mL are avoided. Determination of the adequacy of a serum level for a particular patient must take into consideration the susceptibility of the causative organism, the severity of the infection and the status of the patient’s host-defense mechanisms. In patients with extensive burns, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides. In such patients treated with gentamicin, measurement of serum concentrations is recommended as a basis for dosage adjustment. TABLE 3 DOSAGE SCHEDULE GUIDE FOR ADULTS WITH NORMAL RENAL FUNCTION (Dosage at Eight-Hour Intervals) 40 mg per mL Patient’s Weight* Usual Dose for Serious Infections 1 mg/kg q8h (3 mg/kg/day) Dose for Life-Threatening Infections (Reduce As Soon As Clinically Indicated) 1.7 mg/kg q8h** (5 mg/kg/day) kg (lb) mg/dose mL/dose mg/dose mL/dose q8h q8h 40 ( 88 ) 40 1 66 1.6 45 ( 99) 45 1.1 75 1.9 50 (110) 50 1.25 83 2.1 55 (121) 55 1.4 91 2.25 60 (132) 60 1.5 100 2.5 65 (143) 65 1.6 108 2.7 70 (154) 70 1.75 116 2.9 75 (165) 75 1.9 125 3.1 80 (176) 80 2 133 3.3 85 (187) 85 2.1 141 3.5 90 (198) 90 2.25 150 3.75 95 (209) 95 2.4 158 4 100 (220) 100 2.5 166 4.2 *The dosage of aminoglycosides in obese patients should be based on an estimate of the lean body mass. **for q6h schedules, dosage should be recalculated. Children 6 to 7.5 mg/kg/day (2 to 2.5 mg/kg administered every eight hours). Infants and Neonates 7.5 mg/kg/day (2.5 mg/kg administered every eight hours). Premature or Full-Term Neonates One Week of Age or Less 5 mg/kg/day (2.5 mg/kg administered every 12 hours). For further information concerning the use of gentamicin in infants and children, see gentamicin injection (pediatric) product information. The usual duration of treatment for all patients is 7 to 10 days. In difficult and complicated infections, a longer course of therapy may be necessary. In such cases monitoring of renal, auditory and vestibular functions is recommended, since toxicity is more apt to occur with treatment extended for more than 10 days. Dosage should be reduced if clinically indicated. FOR INTRAVENOUS ADMINISTRATION The IV administration of gentamicin may be particularly useful for treating patients with bacterial septicemia or those in shock. It may also be the preferred route of administration for some patients with congestive heart failure, hematologic disorders, severe burns or those with reduced muscle mass. For intermittent IV administration in adults, a single dose of gentamicin injection may be diluted in 50 to 200 mL of sterile isotonic saline solution or in a sterile solution of dextrose 5% in water; in infants and children, the volume of diluent should be less. The solution may be infused over a period of one-half to two hours. The recommended dosage for IM and IV administration is identical. Gentamicin injection should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule. PATIENTS WITH IMPAIRED RENAL FUNCTION Dosage must be adjusted in patients with impaired renal function to assure therapeutically adequate, but not excessive blood levels. Whenever possible serum concentration of gentamicin should be monitored. One method of dosage adjustment is to increase the interval between administration of the usual doses. Since the serum creatinine concentration has a high correlation with the serum half-life of gentamicin, this laboratory test may provide guidance for adjustment of the interval between doses. The interval between doses (in hours) may be approximated by multiplying the serum creatinine level (mg/100 mL) by 8. For example, a patient weighing 60 kg with a serum creatinine level of 2 mg/100 mL could be given 60 mg (1 mg/kg) every 16 hours (2 x 8). In patients with serious systemic infections and renal impairment, it may be desirable to administer the antibiotic more frequently but in reduced dosage. In such patients, serum concentrations of gentamicin should be measured so that adequate but not excessive levels result. A peak and trough concentration measured intermittently during therapy will provide optimal guidance for adjusting dosage. After the usual initial dose, a rough guide for determining reduced dosage at eight-hour intervals is to divide the normally recommended dose by the serum creatinine level (Table 4) . For example, after an initial dose of 60 mg (1 mg/kg), a patient weighing 60 kg with a serum creatinine level of 2 mg/100 mL could be given 30 mg every eight hours (60 ÷ 2). It should be noted that the status of renal function may be changing over the course of the infectious process. It is important to recognize that deteriorating renal function may require a greater reduction in dosage than that specified in the above guidelines for patients with stable renal impairment. TABLE 4 DOSAGE ADJUSTMENT GUIDE FOR PATIENTS WITH RENAL IMPAIRMENT (Dosage at Eight-Hour Intervals After the Usual Initial Dose) Serum Creatinine (mg %) Approximate Creatinine Clearance Rate (mL/min/1.73m 2 ) Percent of Usual Doses Shown Above ≤1 > 100 100 1.1 to 1.3 70 to 100 80 1.4 to 1.6 55 to 70 65 1.7 to 1.9 45 to 55 55 2 to 2.2 40 to 45 50 2.3 to 2.5 35 to 40 40 2.6 to 3 30 to 35 35 3.1 to 3.5 25 to 30 30 3.6 to 4 20 to 25 25 4.1 to 5.1 15 to 20 20 5.2 to 6.6 10 to 15 15 6.7 to 8 < 10 10 In adults with renal failure undergoing hemodialysis, the amount of gentamicin removed from the blood may vary depending upon several factors including the dialysis method used. An eight-hour hemodialysis may reduce serum concentrations of gentamicin by approximately 50%. The recommended dosage at the end of each dialysis period is 1 to 1.7 mg/kg depending upon the severity of the infection. In children, a dose of 2 mg/kg may be administered. The above dosage schedules are not intended as rigid recommendations but are provided as guides to dosage when measurement of gentamicin serum level is not feasible. A variety of methods are available to measure gentamicin concentrations in body fluids; these include microbiologic, enzymatic and radioimmunoassay techniques. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."],"spl_product_data_elements":["Gentamicin GENTAMICIN SULFATE EDETATE DISODIUM PROPYLPARABEN METHYLPARABEN SODIUM METABISULFITE SODIUM HYDROXIDE SULFURIC ACID WATER GENTAMICIN SULFATE GENTAMICIN"],"clinical_pharmacology_table":["
Susceptibility Interpretive Criteria
Pathogen Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm)
(S) (I) (R) (S) (I) (R)
Enterobacteriaceae a ≤4 8 ≥16 ≥15 13 to 14 ≤12
Pseudomonas aeruginosa ≤4 8 ≥16 ≥15 13 to 14 ≤12
Staphylococcus Species b ≤4 8 ≥16 ≥15 13 to 14 ≤12
","
Quality Control Organism Minimum Inhibitory Concentrations (mcg/mL) Zone Diameter (mm)
Escherichia coli ATCC 25922 0.25 to 1 19 to 26
Pseudomonas aeruginosa ATCC 27853 0.5 to 2 17 to 23
Staphylococcus aureus ATCC 25923 Not Applicable 19 to 27
Staphylococcus aureus ATCC 29213 0.12 to 1 Not Applicable
Enterococcus faecalis ATCC 29212 4 to 16 Not Applicable
","
Susceptibility Interpretive Criteria
Pathogen Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm)
(S) (I) (R) (S) (I) (R)
Enterobacteriaceae a ≤4 8 ≥16 ≥15 13 to 14 ≤12
Pseudomonas aeruginosa ≤4 8 ≥16 ≥15 13 to 14 ≤12
Staphylococcus Species b ≤4 8 ≥16 ≥15 13 to 14 ≤12
","
Quality Control Organism Minimum Inhibitory Concentrations (mcg/mL) Zone Diameter (mm)
Escherichia coli ATCC 25922 0.25 to 1 19 to 26
Pseudomonas aeruginosa ATCC 27853 0.5 to 2 17 to 23
Staphylococcus aureus ATCC 25923 Not Applicable 19 to 27
Staphylococcus aureus ATCC 29213 0.12 to 1 Not Applicable
Enterococcus faecalis ATCC 29212 4 to 16 Not Applicable
"],"dosage_and_administration_table":["
Patient’s Weight* Usual Dose for Serious Infections 1 mg/kg q8h (3 mg/kg/day) Dose for Life-Threatening Infections (Reduce As Soon As Clinically Indicated) 1.7 mg/kg q8h** (5 mg/kg/day)
kg (lb)
mg/dose mL/dose mg/dose mL/dose
q8h q8h
40 ( 88 ) 40 1 66 1.6
45 ( 99) 45 1.1 75 1.9
50 (110) 50 1.25 83 2.1
55 (121) 55 1.4 91 2.25
60 (132) 60 1.5 100 2.5
65 (143) 65 1.6 108 2.7
70 (154) 70 1.75 116 2.9
75 (165) 75 1.9 125 3.1
80 (176) 80 2 133 3.3
85 (187) 85 2.1 141 3.5
90 (198) 90 2.25 150 3.75
95 (209) 95 2.4 158 4
100 (220) 100 2.5 166 4.2
*The dosage of aminoglycosides in obese patients should be based on an estimate of the lean body mass. **for q6h schedules, dosage should be recalculated.
","
Serum Creatinine (mg %) Approximate Creatinine Clearance Rate (mL/min/1.73m 2) Percent of Usual Doses Shown Above
≤1 > 100 100
1.1 to 1.3 70 to 100 80
1.4 to 1.6 55 to 70 65
1.7 to 1.9 45 to 55 55
2 to 2.2 40 to 45 50
2.3 to 2.5 35 to 40 40
2.6 to 3 30 to 35 35
3.1 to 3.5 25 to 30 30
3.6 to 4 20 to 25 25
4.1 to 5.1 15 to 20 20
5.2 to 6.6 10 to 15 15
6.7 to 8 < 10 10
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - VIAL LABEL Gentamicin Injection, USP 80 mg per 2 mL (40 mg per mL*) *Gentamicin equivalent For IM or IV Use. MUST BE DILUTED FOR IV USE. 2 mL Multiple Dose Vial Rx only 73111.pdp","PACKAGE LABEL - PRINCIPAL DISPLAY - Outer Package NDC 71872-7311-1 Gentamicin Injection, USP 80 mg per 2 mL (40 mg per mL*) *Gentamicin equivalent For intramuscular or intravenous use. MUST BE DILUTED FOR IV USE. 1 x 2 mL Multiple Dose Vial Rx only 7311.pdp"]},"tags":[{"label":"Aminoglycoside Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Transient receptor potential cation channel subfamily V member 5","category":"target"},{"label":"TRPV5","category":"gene"},{"label":"DHFR","category":"gene"},{"label":"D06AX07","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Injection","category":"form"},{"label":"Ointment","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Bacterial conjunctivitis","category":"indication"},{"label":"Bacterial infection due to Klebsiella pneumoniae","category":"indication"},{"label":"Bacterial infection due to Serratia","category":"indication"},{"label":"Bacterial infection of skin","category":"indication"},{"label":"Bacterial keratitis","category":"indication"},{"label":"Bacterial meningitis","category":"indication"},{"label":"Schering","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["BOXED WARNINGS Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, gentamicin injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage of prolonged therapy. Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with pre-existing renal damage and in patients with normal renal function treated with higher doses and/or for longer periods than recommended. Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions. Renal and eighth cranial nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Urine should be examined for decreased specific gravity, increased excretion of protein and the presence of cells or casts. Blood urea nitrogen (BUN), serum creatinine or creatinine clearance should be determined periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions changes in renal and eighth cranial nerve function may not become manifest until soon after completion of therapy. Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring gentamicin trough concentrations, dosage should be adjusted so that levels above 2 mcg/mL are avoided. Excessive peak and/or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity. In the event of overdosage or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably lower by peritoneal dialysis than it is by hemodialysis. In the newborn infant, exchange transfusions may also be considered. Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin and viomycin, should be avoided. Other factors which may increase patient risk of toxicity are advanced age and dehydration. The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue. Aminoglycosides can cause fetal harm when administered to a pregnant woman (see WARNINGS section)."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1182 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"1162 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"881 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"823 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"690 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"543 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"495 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"480 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"474 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"468 reports"}],"drugInteractions":[{"url":"/drug/cisatracurium","drug":"cisatracurium","action":"Monitor closely","effect":"May interact with Cisatracurium Besylate","source":"DrugCentral","drugSlug":"cisatracurium"},{"url":"/drug/metocurine","drug":"metocurine","action":"Monitor closely","effect":"May interact with Metocurine Iodide","source":"DrugCentral","drugSlug":"metocurine"},{"url":"/drug/mezlocillin","drug":"mezlocillin","action":"Monitor closely","effect":"May interact with Mezlocillin","source":"DrugCentral","drugSlug":"mezlocillin"},{"url":"/drug/mivacurium","drug":"mivacurium","action":"Monitor closely","effect":"May interact with Mivacurium","source":"DrugCentral","drugSlug":"mivacurium"},{"url":"/drug/pancuronium","drug":"pancuronium","action":"Monitor closely","effect":"May interact with Pancuronium","source":"DrugCentral","drugSlug":"pancuronium"},{"url":"/drug/pentamidine","drug":"pentamidine","action":"Monitor closely","effect":"May interact with Pentamidine","source":"DrugCentral","drugSlug":"pentamidine"},{"url":"/drug/pipecuronium","drug":"pipecuronium","action":"Monitor closely","effect":"May interact with Pipecuronium","source":"DrugCentral","drugSlug":"pipecuronium"},{"url":"/drug/piperacillin","drug":"piperacillin","action":"Monitor closely","effect":"May interact with Piperacillin","source":"DrugCentral","drugSlug":"piperacillin"},{"url":"/drug/rocuronium","drug":"rocuronium","action":"Monitor closely","effect":"May interact with Rocuronium Bromide","source":"DrugCentral","drugSlug":"rocuronium"},{"url":"/drug/suxamethonium","drug":"suxamethonium","action":"Monitor closely","effect":"May interact with Succinylcholine","source":"DrugCentral","drugSlug":"suxamethonium"},{"url":"/drug/ticarcillin","drug":"ticarcillin","action":"Monitor closely","effect":"May interact with Ticarcillin","source":"DrugCentral","drugSlug":"ticarcillin"},{"url":"/drug/torsemide","drug":"torsemide","action":"Monitor closely","effect":"May interact with Torsemide","source":"DrugCentral","drugSlug":"torsemide"},{"url":"/drug/tubocurarine","drug":"tubocurarine","action":"Monitor closely","effect":"May interact with Tubocurarine","source":"DrugCentral","drugSlug":"tubocurarine"},{"url":"/drug/vancomycin","drug":"vancomycin","action":"Monitor closely","effect":"May interact with Vancomycin","source":"DrugCentral","drugSlug":"vancomycin"},{"url":"/drug/vecuronium","drug":"vecuronium","action":"Monitor closely","effect":"May interact with Vecuronium","source":"DrugCentral","drugSlug":"vecuronium"}],"commonSideEffects":[{"effect":"ocular burning","drugRate":"reported","severity":"unknown"},{"effect":"irritation upon drug instillation","drugRate":"reported","severity":"unknown"},{"effect":"non-specific conjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"conjunctival epithelial defects","drugRate":"reported","severity":"unknown"},{"effect":"conjunctival hyperemia","drugRate":"reported","severity":"unknown"},{"effect":"allergic reactions","drugRate":"reported","severity":"unknown"},{"effect":"thrombocytopenic purpura","drugRate":"reported","severity":"unknown"},{"effect":"hallucinations","drugRate":"reported","severity":"unknown"},{"effect":"bacterial and fungal corneal ulcers","drugRate":"reported","severity":"unknown"}],"contraindications":["Bacterial infection of eye","Dehydration","Denuded skin","Diabetes mellitus","Disorder of the 8th Cranial Nerve","Eye infection","Fungal infection of eye","Gentamicin Toxicity","Herpes simplex dendritic keratitis","Herpes simplex keratitis","Hypocalcemia","Infant Botulism","Kidney disease","Krukenberg spindle","Myasthenia gravis","Ocular hypertension","Open-angle glaucoma","Parkinsonism","Pregnancy, function","Severe myopia","Tinnitus","Tuberculosis of eye","Vaccinia keratitis","Vertigo","Viral eye infection"],"specialPopulations":{"Pregnancy":"Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.","Paediatric use":"Safety and effectiveness in neonates have not been established.","Renal impairment":"the risk of toxic reactions to this drug may be greater in patients with impaired renal function"}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.0274/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$375","description":"GENTAMICIN 0.1% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GENTAMICIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:08:05.148133+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:08:11.447675+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:08:04.267576+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GENTAMICIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:08:11.762950+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:08:00.046352+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"BOXED WARNINGS Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, gentamicin injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage of prolonged therapy. Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primari","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:08:00.046392+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:08:13.291818+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067485/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:08:12.468657+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA062366","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:08:00.046397+00:00"}},"allNames":"garamycin","offLabel":[],"synonyms":["gentamicin sulfate","gentamicin","alcomicin","gentacin","gentamicine sulfate"],"timeline":[{"date":"1963-01-01","type":"neutral","_source":"Wikipedia","milestone":"Gentamicin discovery","regulator":"none"},{"date":"1980-06-05","type":"positive","_source":"FDA ANDA062251","milestone":"FDA ORIG — HIKMA","regulator":"FDA","description":""},{"date":"1980-07-02","type":"positive","_source":"FDA ANDA062196","milestone":"FDA ORIG — SANDOZ","regulator":"FDA","description":""},{"date":"1981-05-15","type":"positive","_source":"FDA ANDA062307","milestone":"FDA ORIG — PADAGIS US","regulator":"FDA","description":""},{"date":"1982-02-18","type":"positive","_source":"FDA ANDA062351","milestone":"FDA ORIG — PADAGIS US","regulator":"FDA","description":""},{"date":"1982-09-07","type":"positive","_source":"FDA ANDA062373","milestone":"FDA ORIG — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1983-08-04","type":"positive","_source":"FDA ANDA062366","milestone":"FDA ORIG — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1983-08-15","type":"positive","_source":"FDA ANDA062420","milestone":"FDA ORIG — HOSPIRA","regulator":"FDA","description":""},{"date":"1987-05-22","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1987-07-13","type":"positive","_source":"FDA ANDA062351","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"1988-02-22","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1989-05-12","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1990-09-11","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1990-11-19","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1991-02-07","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1991-02-08","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1991-03-18","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1992-08-27","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1993-05-21","type":"positive","_source":"FDA ANDA062307","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"1993-06-22","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1993-07-13","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"1993-08-04","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1993-09-16","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1994-02-03","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1994-02-25","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1994-04-29","type":"positive","_source":"FDA ANDA064054","milestone":"FDA ORIG — COSETTE","regulator":"FDA","description":""},{"date":"1994-05-11","type":"positive","_source":"FDA ANDA064048","milestone":"FDA ORIG — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"1994-09-09","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"1994-12-06","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"1995-01-27","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1995-12-28","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"1996-07-12","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"1996-08-26","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"1996-10-03","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"1997-05-21","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1997-06-09","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"1998-01-14","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"1998-04-03","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"1998-09-18","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"1999-02-11","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"1999-05-07","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"1999-06-07","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"2000-01-07","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2000-03-07","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2000-04-07","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"2000-04-28","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"2000-09-18","type":"positive","_source":"FDA ANDA062307","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"2001-03-07","type":"positive","_source":"FDA ANDA064048","milestone":"FDA SUPPL — BAUSCH AND LOMB","regulator":"FDA","description":""},{"date":"2001-03-22","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2001-07-23","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"2001-12-28","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2002-03-14","type":"positive","_source":"FDA ANDA062351","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"2002-10-25","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2002-12-05","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2002-12-23","type":"positive","_source":"FDA ANDA062196","milestone":"FDA SUPPL — SANDOZ","regulator":"FDA","description":""},{"date":"2003-05-09","type":"positive","_source":"FDA ANDA062307","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"2004-04-21","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2004-05-03","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2004-08-31","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2005-03-09","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2007-11-05","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2009-04-17","type":"positive","_source":"FDA ANDA062307","milestone":"FDA SUPPL — PADAGIS US","regulator":"FDA","description":""},{"date":"2009-11-30","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2013-07-26","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2013-07-30","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2014-03-07","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2015-12-11","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2022-02-15","type":"positive","_source":"FDA ANDA062251","milestone":"FDA SUPPL — HIKMA","regulator":"FDA","description":""},{"date":"2023-01-31","type":"positive","_source":"FDA ANDA062373","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2023-02-01","type":"positive","_source":"FDA ANDA062420","milestone":"FDA SUPPL — HOSPIRA","regulator":"FDA","description":""},{"date":"2023-02-10","type":"positive","_source":"FDA ANDA062366","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2024-01-08","type":"positive","_source":"FDA ANDA215236","milestone":"FDA ORIG — EUGIA PHARMA","regulator":"FDA","description":""}],"approvals":[{"date":"1970-06-19","orphan":false,"company":"SCHERING","regulator":"FDA"}],"brandName":"Garamycin","ecosystem":[{"indication":"Bacterial conjunctivitis","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"besifloxacin","slug":"besifloxacin","company":"Bausch And Lomb"},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"}],"globalPrevalence":null},{"indication":"Bacterial infection due to Klebsiella pneumoniae","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Bacterial infection due to Serratia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Bacterial infection of skin","otherDrugs":[{"name":"chloramphenicol","slug":"chloramphenicol","company":"Parkedale"},{"name":"dalbavancin","slug":"dalbavancin","company":"Durata Theraps Intl"},{"name":"delafloxacin","slug":"delafloxacin","company":"Melinta Therapeutics Inc"},{"name":"omadacycline","slug":"omadacycline","company":"Paratek Pharms Inc"}],"globalPrevalence":null},{"indication":"Bacterial keratitis","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"bacitracin","slug":"bacitracin","company":"Pharmacia And Upjohn"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":6000000},{"indication":"Bacterial meningitis","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"},{"name":"ceftazidime","slug":"ceftazidime","company":"Covis Injectables"}],"globalPrevalence":null},{"indication":"Bacterial pneumonia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null}],"mechanism":{"target":"Transient receptor potential cation channel subfamily V member 5","novelty":"Follow-on","targets":[{"gene":"TRPV5","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily V member 5","protein":"Transient receptor potential cation channel subfamily V member 5"},{"gene":"DHFR","source":"DrugCentral","target":"Dihydrofolate reductase","protein":"Dihydrofolate reductase"}],"modality":"Small Molecule","drugClass":"Aminoglycoside Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Garamycin exerts its antibacterial effect by binding to the transient receptor potential cation channel subfamily V member 5 (TRPV5), a calcium channel involved in the regulation of calcium homeostasis in bacterial cells. This binding disrupts the normal functioning of the channel, leading to an influx of calcium ions and subsequent cell death."},"commercial":{"yoyGrowth":"7%","launchDate":"1970","annualCostUS":"$0.50-$1.50","_launchSource":"DrugCentral (FDA 1970-06-19, SCHERING)","genericStatus":"Generic — off-patent","manufacturerCount":"7 approved manufacturers","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"21.2B"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4265","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GENTAMICIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GENTAMICIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:44:33.274132","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:15.673146+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Ciprofloxacin","company":"Brand Names: Cipro","advantage":"Effective antibiotic that treats a wide variety of infections"},{"name":"Cephalexin","company":"Brand Names: Keflex","advantage":"Cephalosporin-type antibiotic that may be used to treat infections caused by susceptible bacteria"},{"name":"Levofloxacin","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection and Kidney Infections"},{"name":"Ceftriaxone","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bone infection and Bacterial Infection"},{"name":"Metronidazole","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bone infection and Bacterial Infection"},{"name":"Clindamycin","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection and Bone infection"},{"name":"Doxycycline","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection"},{"name":"Amoxicillin","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection"},{"name":"Augmentin","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection and Kidney Infections"},{"name":"Amoxicillin / clavulanate","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bacterial Infection"},{"name":"Keflex","company":"Brand Names: Keflex","advantage":"Cephalosporin-type antibiotic that may be used to treat infections caused by susceptible bacteria"},{"name":"Bactrim","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Kidney Infections"},{"name":"Sulfamethoxazole / trimethoprim","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Kidney Infections"},{"name":"Vancomycin","company":"Brand Names: Not specified","advantage":"Effective antibiotic for Bone infection"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"gentamicin","indications":{"approved":[{"name":"Bacterial conjunctivitis","source":"DrugCentral","snomedId":128350005,"regulator":"FDA","eligibility":"Adults and children with bacterial conjunctivitis"},{"name":"Bacterial infection due to Klebsiella pneumoniae","source":"DrugCentral","snomedId":186435004,"regulator":"FDA","eligibility":"Adults and children with bacterial infections caused by Klebsiella pneumoniae"},{"name":"Bacterial infection due to Serratia","source":"DrugCentral","snomedId":71120004,"regulator":"FDA","eligibility":"Adults and children with bacterial infections caused by Serratia"},{"name":"Bacterial infection of skin","source":"DrugCentral","snomedId":128936008,"regulator":"FDA","eligibility":"Adults and children with bacterial skin infections"},{"name":"Bacterial keratitis","source":"DrugCentral","snomedId":314557000,"regulator":"FDA","eligibility":"Adults and children with bacterial keratitis","usPrevalence":null,"globalPrevalence":6000000,"prevalenceMethod":"curated","prevalenceSource":"Cochrane Database Syst Rev, 2025 (PMID:40728038)"},{"name":"Bacterial meningitis","source":"DrugCentral","snomedId":95883001,"regulator":"FDA","eligibility":"Adults and children with bacterial meningitis"},{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA","eligibility":"Adults and children with bacterial pneumonia"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA","eligibility":"Adults and children with bacterial septicemia"},{"name":"Blepharoconjunctivitis","source":"DrugCentral","snomedId":68659002,"regulator":"FDA","eligibility":"Adults and children with blepharoconjunctivitis"},{"name":"Burn Wound Infections","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children with burn wound infections"},{"name":"Cholangitis","source":"DrugCentral","snomedId":82403002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":648000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22245904[PMID])"},{"name":"Citrobacter Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Citrobacter Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Complicated Bacterial Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Complicated UTI with Pseudomonas Aeruginosa","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Complicated Urinary Tract Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Dacryocystitis","source":"DrugCentral","snomedId":85777005,"regulator":"FDA"},{"name":"Enterobacter Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Folliculitis","source":"DrugCentral","snomedId":13600006,"regulator":"FDA"},{"name":"Furunculosis","source":"DrugCentral","snomedId":112650006,"regulator":"FDA"},{"name":"Gram-Negative Aerobic Bacillary Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Infection due to Enterobacteriaceae","source":"DrugCentral","snomedId":128945009,"regulator":"FDA"},{"name":"Infection due to Escherichia coli","source":"DrugCentral","snomedId":71057007,"regulator":"FDA"},{"name":"Infection due to Pseudomonas aeruginosa","source":"DrugCentral","snomedId":11218009,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Infective blepharitis","source":"DrugCentral","snomedId":312219000,"regulator":"FDA"},{"name":"Klebsiella Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Meibomianitis","source":"DrugCentral","snomedId":309779001,"regulator":"FDA"},{"name":"Neonatal meningitis","source":"DrugCentral","snomedId":276674008,"regulator":"FDA"},{"name":"Neonatal pneumonia","source":"DrugCentral","snomedId":233619008,"regulator":"FDA"},{"name":"Paronychia","source":"DrugCentral","snomedId":71906005,"regulator":"FDA"},{"name":"Peritonitis","source":"DrugCentral","snomedId":48661000,"regulator":"FDA"},{"name":"Pneumonia due to Escherichia coli","source":"DrugCentral","snomedId":51530003,"regulator":"FDA"},{"name":"Pneumonia due to Pseudomonas","source":"DrugCentral","snomedId":41381004,"regulator":"FDA"},{"name":"Proteus pneumonia","source":"DrugCentral","snomedId":195888009,"regulator":"FDA"},{"name":"Proteus septicemia","source":"DrugCentral","snomedId":300986008,"regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Biliary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Rhinoscleroma","source":"DrugCentral","snomedId":72409005,"regulator":"FDA"},{"name":"Sepsis due to Gram negative bacteria","source":"DrugCentral","snomedId":449082003,"regulator":"FDA"},{"name":"Sepsis due to Pseudomonas","source":"DrugCentral","snomedId":448813005,"regulator":"FDA"},{"name":"Sepsis of the newborn","source":"DrugCentral","snomedId":206376005,"regulator":"FDA"},{"name":"Septicemia due to Escherichia coli","source":"DrugCentral","snomedId":9323009,"regulator":"FDA"},{"name":"Septicemia due to Serratia","source":"DrugCentral","snomedId":82091000,"regulator":"FDA"},{"name":"Skin and Skin Structure Citrobacter Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Proteus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":251400000,"prevalenceMethod":"curated","prevalenceSource":"Pathogens, 2024 (PMID:39452777)"},{"name":"Skin and Skin Structure Pseudomonas Aeruginosa Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Serratia Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Bacterial Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Citrobacter Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Enterobacter Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Escherichia Coli Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Group B Streptococcal Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Klebsiella Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Neonatal Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Proteus Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Pseudomonas Aeruginosa Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Pseudomonas Aeruginosa Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Pseudomonas Aeruginosa Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Pseudomonas Aeruginosa Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Pseudomonas Aeruginosa Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Serratia Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Skin and Skin Structure Pseudomonas Aeruginosa Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcal Endocarditis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcal Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcal Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcal Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcus Aureus Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Synergy for Staphylococcus Skin and Skin Structure Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Ecthyma gangrenosum","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":14,"evidenceLevel":"moderate"},{"name":"Enteric campylobacteriosis","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":39,"evidenceLevel":"moderate"},{"name":"Infection by Campylobacter fetus","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":56,"evidenceLevel":"strong"},{"name":"Infection by Yersinia enterocolitica","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Listeria Monocytogenes Septicemia","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":57,"evidenceLevel":"strong"},{"name":"Necrotizing enterocolitis in fetus OR newborn","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":904337,"evidenceLevel":"strong"},{"name":"Plague","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":59,"evidenceLevel":"strong"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":133,"evidenceLevel":"strong"},{"name":"Pseudomonas Respiratory Tract Infection in Cystic Fibrosis","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":47,"evidenceLevel":"moderate"},{"name":"Pseudotuberculosis","source":"DrugCentral","drugName":"GENTAMICIN","evidenceCount":34,"evidenceLevel":"moderate"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Synergy for Enterococcal Endocarditis","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Synergy for Enterococcal Infections","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Synergy for Listeria Monocytogenes Septicemia","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Synergy for Prevention of Enterococcal Endocarditis","source":"DrugCentral","drugName":"GENTAMICIN"},{"name":"Synergy for Streptococcal Endocarditis","source":"DrugCentral","drugName":"GENTAMICIN"}],"pipeline":[]},"currentOwner":"Schering","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"chloramphenicol","brandName":"chloramphenicol","genericName":"chloramphenicol","approvalYear":"1950","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-class"},{"drugId":"mupirocin","brandName":"mupirocin","genericName":"mupirocin","approvalYear":"1987","relationship":"same-class"},{"drugId":"virginiamycin","brandName":"virginiamycin","genericName":"virginiamycin","approvalYear":"","relationship":"same-class"},{"drugId":"rifaximin","brandName":"rifaximin","genericName":"rifaximin","approvalYear":"2004","relationship":"same-class"},{"drugId":"amikacin","brandName":"amikacin","genericName":"amikacin","approvalYear":"1981","relationship":"same-class"},{"drugId":"retapamulin","brandName":"retapamulin","genericName":"retapamulin","approvalYear":"2007","relationship":"same-class"},{"drugId":"ozenoxacin","brandName":"ozenoxacin","genericName":"ozenoxacin","approvalYear":"2017","relationship":"same-class"},{"drugId":"rifamycin","brandName":"rifamycin","genericName":"rifamycin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03132116","phase":"PHASE3","title":"Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-31","conditions":["Cat-Scratch Disease"],"enrollment":75,"completionDate":"2025-08-21"},{"nctId":"NCT07478874","phase":"NA","title":"Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-07-01","conditions":["Surgical Site Infection (SSI)"],"enrollment":284,"completionDate":"2025-12-31"},{"nctId":"NCT05421741","phase":"PHASE4","title":"Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-05-15","conditions":["Osteomyelitis Tibia","Tibial Fractures","Open Tibia Fracture"],"enrollment":484,"completionDate":"2027-12"},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":["Sepsis"],"enrollment":1900,"completionDate":"2033-05"},{"nctId":"NCT07470112","phase":"NA","title":"Efficacy of Local Gentamicin Containing Collagen In Prevention of Post Stermotomy Infection In Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2025-05-20","conditions":["Surgical Site Infection (SSI)"],"enrollment":142,"completionDate":"2026-05"},{"nctId":"NCT05164081","phase":"PHASE3","title":"Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Umeå University","startDate":"2022-01-01","conditions":["Femoral Neck Fractures","Prosthetic Infection"],"enrollment":7000,"completionDate":"2027-01-31"},{"nctId":"NCT07460349","phase":"","title":"Extended Interval Dosing of Gentamicin in Neonates","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-03","conditions":["Early Onset Sepsis"],"enrollment":42,"completionDate":"2026-05"},{"nctId":"NCT02725463","phase":"NA","title":"Multichannel Vestibular Implant Early Feasibility Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2016-04","conditions":["Other Disorders of Vestibular Function, Bilateral","Bilateral Vestibular Deficiency (BVD)","Gentamicin Ototoxicity","Labyrinth Diseases","Vestibular Diseases","Sensation Disorders"],"enrollment":30,"completionDate":"2028-03-31"},{"nctId":"NCT06500975","phase":"NA","title":"Long Term Outcomes After Vestibular Implantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-12-01","conditions":["Bilateral Vestibular Hypofunction","Bilateral Vestibular Deficiency","Bilateral Vestibulopathy","Gentamicin Ototoxicity","Aminoglycoside Toxicity","Vestibular Diseases","Sensation Disorders","Labyrinth Diseases","Other Disorders of Vestibular Function"],"enrollment":32,"completionDate":"2029-12"},{"nctId":"NCT07407491","phase":"PHASE2","title":"Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis","status":"RECRUITING","sponsor":"National University of Malaysia","startDate":"2024-07-09","conditions":["Acute Cholangitis","Biliary Tract Infection","Biliary Obstruction","Choledocholithiasis","Malignant Biliary Stricture"],"enrollment":172,"completionDate":"2026-07-08"},{"nctId":"NCT04731025","phase":"PHASE3","title":"Local Antibiotics for Breast Implants","status":"RECRUITING","sponsor":"Mikkel Herly","startDate":"2021-01-27","conditions":["Implant Complication","Implant Infection","Implant Site Infection","Implant Capsular Contracture","Implant Site Pocket Infection","Implant Expulsion","Antibiotic Side Effect"],"enrollment":1003,"completionDate":"2027-08"},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":["Infective Endocarditis"],"enrollment":324,"completionDate":"2023-06-24"},{"nctId":"NCT07390591","phase":"","title":"Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms","status":"RECRUITING","sponsor":"Medstar Health Research Institute","startDate":"2025-06-19","conditions":["Spinal Cord Injuries","Neurogenic Lower Urinary Tract Dysfunction","Neurogenic Bladder"],"enrollment":60,"completionDate":"2027-09"},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":["Cholangitis"],"enrollment":440,"completionDate":"2026-09-01"},{"nctId":"NCT04039750","phase":"PHASE2","title":"Use of Antibiotic Irrigation to Decrease Wound Infections in Pediatric Perforated Appendicitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2019-07-25","conditions":["Perforated Appendicitis"],"enrollment":200,"completionDate":"2026-12"},{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":["Arthropathy of Knee","Antibiotic Prophylaxis"],"enrollment":1770,"completionDate":"2025-08-22"},{"nctId":"NCT06332781","phase":"PHASE4","title":"Intravesical Gentamicin to Prevent Recurrent UTI","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-04-28","conditions":["Recurrent Uti"],"enrollment":30,"completionDate":"2026-05-31"},{"nctId":"NCT05659329","phase":"","title":"Retrospective Simplex High Viscosity (HV) Bone Cement Study","status":"COMPLETED","sponsor":"Stryker Orthopaedics","startDate":"2016-04-25","conditions":["Arthritis Knee","Aseptic Loosening"],"enrollment":200,"completionDate":"2022-09-27"},{"nctId":"NCT05676944","phase":"NA","title":"Vestibular Implantation in Older Adults","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-11","conditions":["Other Disorders of Vestibular Function, Bilateral","Bilateral Vestibular Deficiency (BVD)","Gentamicin Ototoxicity","Labyrinth Diseases","Vestibular Diseases","Sensation Disorders","Bilateral Vestibular Hypofunction","Bilateral Vestibulopathy","Presbyvestibulopathy","Aminoglycoside Ototoxicity"],"enrollment":15,"completionDate":"2028-01-31"},{"nctId":"NCT05674786","phase":"NA","title":"Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-02-28","conditions":["Other Disorders of Vestibular Function, Bilateral","Bilateral Vestibular Deficiency (BVD)","Gentamicin Ototoxicity","Labyrinth Diseases","Vestibular Diseases","Sensation Disorders","Bilateral Vestibular Hypofunction","Bilateral Vestibulopathy","Aminoglycoside Ototoxicity"],"enrollment":8,"completionDate":"2027-03-31"},{"nctId":"NCT03481881","phase":"","title":"Pharmacokinetics of Drugs Administered to Children","status":"RECRUITING","sponsor":"Duke University","startDate":"2013-08-14","conditions":["Pediatric ALL"],"enrollment":200,"completionDate":"2033-08-14"},{"nctId":"NCT06489431","phase":"PHASE3","title":"Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2023-12-04","conditions":["Erectile Dysfunction","Penile Prosthesis; Complications, Infection or Inflammation"],"enrollment":200,"completionDate":"2027-12-31"},{"nctId":"NCT07311395","phase":"NA","title":"Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2025-12-08","conditions":["Surgical Site Infection"],"enrollment":100,"completionDate":"2026-01-07"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT05766670","phase":"PHASE3","title":"Intramedullary Calcium Sulfate Antibiotic Depot","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-04-08","conditions":["Open tíbia Fracture","Osteomyelitis Tibia","Tibial Fractures"],"enrollment":497,"completionDate":"2028-01"},{"nctId":"NCT07270380","phase":"NA","title":"Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.","status":"NOT_YET_RECRUITING","sponsor":"Biocomposites Ltd","startDate":"2026-01","conditions":["Osteomyelitis"],"enrollment":139,"completionDate":"2028-07"},{"nctId":"NCT02309346","phase":"PHASE4","title":"Clindamycin Once a Day in Septic Abortion","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12-17","conditions":["Septic Abortion"],"enrollment":202,"completionDate":"2023-12-31"},{"nctId":"NCT07220967","phase":"PHASE4","title":"A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-21","conditions":["Breast Cancer"],"enrollment":392,"completionDate":"2027-10"},{"nctId":"NCT04876131","phase":"PHASE4","title":"Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-30","conditions":["Complicated Urinary Tract Infection","Infection","Pediatric Infectious Disease"],"enrollment":452,"completionDate":"2028-05-16"},{"nctId":"NCT06699134","phase":"","title":"Hi-Fatigue G Bone Cement Retrospective Study","status":"RECRUITING","sponsor":"Zimmer Biomet","startDate":"2024-11-19","conditions":["Total Hip and Knee Arthroplasties"],"enrollment":90,"completionDate":"2026-10"},{"nctId":"NCT06699160","phase":"","title":"Refobacin Revision-3 Bone Cement Post-Market Study","status":"WITHDRAWN","sponsor":"Zimmer Biomet","startDate":"2025-08","conditions":["Revision Arthroplasty"],"enrollment":0,"completionDate":"2030-12"},{"nctId":"NCT02850029","phase":"","title":"An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2016-05-21","conditions":["Underdosing of Aminoglycosides","Critical Illness"],"enrollment":964,"completionDate":"2017-12-31"},{"nctId":"NCT02898961","phase":"PHASE4","title":"Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2014-10","conditions":["Sepsis"],"enrollment":63,"completionDate":"2016-12-31"},{"nctId":"NCT04482140","phase":"","title":"Post Approval Study to Evaluate the Safety and Performance of GENTA-FOIL Resorb® in Hand Surgery","status":"TERMINATED","sponsor":"Advanced Medical Solutions Ltd.","startDate":"2024-10-14","conditions":["Tissue Adhesions, Surgery-Induced"],"enrollment":15,"completionDate":"2025-11-07"},{"nctId":"NCT06555848","phase":"","title":"CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure","status":"RECRUITING","sponsor":"BONESUPPORT AB","startDate":"2025-06-02","conditions":["Osteomyelitis"],"enrollment":128,"completionDate":"2032-10"},{"nctId":"NCT06010433","phase":"","title":"CERAMENT G Device Registry","status":"RECRUITING","sponsor":"BONESUPPORT AB","startDate":"2023-08-17","conditions":["Chronic Osteomyelitis","Fracture Related Infection","Diabetic Foot Osteomyelitis"],"enrollment":100,"completionDate":"2028-09-22"},{"nctId":"NCT03997266","phase":"PHASE4","title":"NICU Antibiotics and Outcomes Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Morowitz","startDate":"2020-08-05","conditions":["Microbial Colonization","Extreme Prematurity","Early-Onset Neonatal Sepsis","Late-Onset Neonatal Sepsis","Necrotizing Enterocolitis of Newborn","Death; Neonatal"],"enrollment":802,"completionDate":"2027-06-01"},{"nctId":"NCT03915366","phase":"PHASE2,PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":["Pneumonia","HIV/AIDS","Tuberculosis","Cytomegalovirus Infections"],"enrollment":563,"completionDate":"2025-01-31"},{"nctId":"NCT07107477","phase":"PHASE3","title":"TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden","status":"RECRUITING","sponsor":"The Central and Eastern European Gynecologic Oncology Group","startDate":"2025-05-01","conditions":["Preterm Premature Rupture of Membranes (PPROM)"],"enrollment":138,"completionDate":"2028-05-01"},{"nctId":"NCT05469984","phase":"NA","title":"Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2022-11-25","conditions":["Preterm Labor With Preterm Delivery","Premature Rupture of Membranes Prolonged"],"enrollment":600,"completionDate":"2025-09-26"},{"nctId":"NCT00814905","phase":"NA","title":"Treatment of Chorioamnionitis After Delivery","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, Portsmouth","startDate":"2008-11-18","conditions":["Chorioamnionitis"],"enrollment":0,"completionDate":"2012-09"},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":["Drug Resistance","Bacterial","Bacteremia"],"enrollment":108000,"completionDate":"2026-08-16"},{"nctId":"NCT06209047","phase":"PHASE4","title":"Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis","status":"RECRUITING","sponsor":"Assiut University","startDate":"2023-10-15","conditions":["Bronchiectasis With Acute Exacerbation"],"enrollment":315,"completionDate":"2027-02-01"},{"nctId":"NCT06332040","phase":"PHASE4","title":"Gentamicin Bladder Instillation on CAUTI","status":"RECRUITING","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2023-10-09","conditions":["Catheter Infection"],"enrollment":400,"completionDate":"2026-10-08"},{"nctId":"NCT05578560","phase":"NA","title":"The Use of Virtual Reality in Rehabilitation in Patients After Vestibular Schwannoma Surgery.","status":"RECRUITING","sponsor":"Charles University, Czech Republic","startDate":"2020-01-01","conditions":["Acute Peripheral Vestibulopathy Following Surgical Procedure"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT05287425","phase":"PHASE2","title":"The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2019-08-12","conditions":["Nasal and Pharyngeal Microbiome"],"enrollment":20,"completionDate":"2023-08-28"},{"nctId":"NCT05157126","phase":"PHASE4","title":"Gentamicin Open Tibia Study","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-09-01","conditions":["Fracture Open Tibia"],"enrollment":890,"completionDate":"2029-04"},{"nctId":"NCT06906354","phase":"NA","title":"Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-11-11","conditions":["Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation"],"enrollment":60,"completionDate":"2025-01-20"},{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":["Interstitial Cystitis"],"enrollment":26,"completionDate":"2025-10-31"},{"nctId":"NCT04110340","phase":"PHASE3","title":"Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-02-15","conditions":["Plague, Bubonic","Plague, Pneumonic"],"enrollment":222,"completionDate":"2025-02-05"},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":["Nephrolithiasis","Urinary Tract Infection (UTI)","Sepsis"],"enrollment":330,"completionDate":"2025-03"},{"nctId":"NCT06841003","phase":"PHASE3","title":"Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis","status":"NOT_YET_RECRUITING","sponsor":"Spaarne Gasthuis","startDate":"2025-02","conditions":["Complicated Appendicitis","Intra-Abdominal Abscess"],"enrollment":752,"completionDate":"2027-05"},{"nctId":"NCT05554211","phase":"PHASE2","title":"Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2022-07-12","conditions":["Breast Cancer","BRCA Mutation"],"enrollment":0,"completionDate":"2024-07-01"},{"nctId":"NCT06387147","phase":"PHASE3","title":"ORal Antibiotics in Acute Mesenteric Ischemia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-31","conditions":["Acute Mesenteric Ischemia"],"enrollment":196,"completionDate":"2027-11-01"},{"nctId":"NCT06814223","phase":"PHASE4","title":"Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-10-28","conditions":["Infection Catheter-Related"],"enrollment":200,"completionDate":"2028-06-30"},{"nctId":"NCT04893733","phase":"PHASE4","title":"Intravenous Administration of Vitamin B Complex Improves Renal Recovery in Patients With AKI","status":"COMPLETED","sponsor":"Caja Nacional de Salud","startDate":"2020-09-01","conditions":["Acute Kidney Injury"],"enrollment":260,"completionDate":"2022-04-30"},{"nctId":"NCT03931408","phase":"PHASE2","title":"Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2019-02-19","conditions":["Neurogenic Bladder","Spinal Cord Injuries"],"enrollment":6,"completionDate":"2020-12-30"},{"nctId":"NCT06792864","phase":"PHASE3","title":"Effectiveness of 3D Bone Matrix in Cranioplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Universidad Austral de Chile","startDate":"2024-07-01","conditions":["Cranioplasty","Craniotomy","Craniotomy Clipping","Craniotomy Surgery","Craniocerebral Trauma","Craniocerebral Injuries"],"enrollment":8,"completionDate":"2025-12-01"},{"nctId":"NCT05929599","phase":"NA","title":"Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Children's Hospital, Vietnam","startDate":"2023-07-05","conditions":["Acute Respiratory Tract Infections","Pneumonia","Respiratory Syncytial Virus (RSV)"],"enrollment":120,"completionDate":"2025-03"},{"nctId":"NCT03845790","phase":"PHASE1","title":"Pharmacokinetic Study of Vancomycin, Clindamycin And/or Gentamicin Administration During Surgery Using a Microdialysis Procedure","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2019-05-26","conditions":["Surgical Site Infection"],"enrollment":25,"completionDate":"2024-09-04"},{"nctId":"NCT06007352","phase":"PHASE2","title":"Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2024-10","conditions":["Urinary Tract Infections","Sepsis"],"enrollment":0,"completionDate":"2025-10"},{"nctId":"NCT04979598","phase":"","title":"Unravelling Risk Factors for Chronic Dizziness in Patients After an Acute Unilateral Vestibular Deafferentiation.","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-06-03","conditions":["Acute Unilateral Vestibular Deafferentiation"],"enrollment":103,"completionDate":"2024-11-01"},{"nctId":"NCT05502380","phase":"PHASE3","title":"Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery","status":"RECRUITING","sponsor":"Balgrist University Hospital","startDate":"2022-09-15","conditions":["Surgical Site Infection","Microbial Colonization","Antibiotic Resistant Infection"],"enrollment":1100,"completionDate":"2025-12-12"},{"nctId":"NCT04921436","phase":"NA","title":"Modulation of Microbiota Metabolism in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2021-10-03","conditions":["Multiple Organ Dysfunction"],"enrollment":60,"completionDate":"2023-07-31"},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":["Bacteremia"],"enrollment":265,"completionDate":"2024-11-19"},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":["Pancreatic Cancer"],"enrollment":344,"completionDate":"2026-01"},{"nctId":"NCT06362447","phase":"PHASE2","title":"Efficacy of Injectable Gentamicin in Hereditary Ichthyosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-09","conditions":["Ichthyosis"],"enrollment":26,"completionDate":"2027-04-01"},{"nctId":"NCT04755179","phase":"","title":"Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population","status":"COMPLETED","sponsor":"Ramon Gorter","startDate":"2019-08-12","conditions":["Appendicitis","Appendix Mass","Appendicitis Perforated"],"enrollment":1308,"completionDate":"2024-07-03"},{"nctId":"NCT04805164","phase":"NA","title":"Evaluation of the Efficiency of the Bone Substitute Cerament-G Locally Delivering Gentamicin in the Treatment of Chronic Osteomyelitis of Long Bones","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-10-14","conditions":["Osteomyelitis Chronic"],"enrollment":220,"completionDate":"2027-11-14"},{"nctId":"NCT04041791","phase":"PHASE3","title":"A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-08-19","conditions":["Pneumonia"],"enrollment":4392,"completionDate":"2024-04-05"},{"nctId":"NCT03503513","phase":"PHASE2,PHASE3","title":"Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-08-24","conditions":["Urinary Tract Infections","Spinal Cord Injuries","Spinal Cord Diseases","Neurogenic Bladder"],"enrollment":23,"completionDate":"2023-09-30"},{"nctId":"NCT06454643","phase":"NA","title":"Gentamicin in Cardiac Surgery","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2020-01-01","conditions":["Cardiac Infection"],"enrollment":50,"completionDate":"2021-01-01"},{"nctId":"NCT02784821","phase":"PHASE2","title":"Antibiotic \"Dysbiosis\" in Preterm Infants","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-01-16","conditions":["Enterocolitis, Necrotizing","Bacteremia","Bronchopulmonary Dysplasia","Intraventricular Hemorrhage","Periventricular Leukomalacia","Chronic Lung Disease","Ileal Perforation"],"enrollment":98,"completionDate":"2019-09-11"},{"nctId":"NCT04789928","phase":"PHASE1","title":"Conservative Treatment of Catheter - Related Injections With Gentamicine/EDTA","status":"COMPLETED","sponsor":"Institut Pasteur","startDate":"2021-01-05","conditions":["Patients With Uncomplicated Long-term Central Venous Catheter-related Biofilm-related Infection"],"enrollment":8,"completionDate":"2024-03-01"},{"nctId":"NCT06428448","phase":"PHASE2","title":"Study to Evaluate the REMEDY SPECTRUM IM Spacer Nail in the Treatment of Ankle-Related Infections","status":"NOT_YET_RECRUITING","sponsor":"OsteoRemedies, LLC","startDate":"2024-08","conditions":["Periprosthetic Joint Infection"],"enrollment":60,"completionDate":"2026-08"},{"nctId":"NCT05303909","phase":"PHASE2","title":"The Immunostimulatory Effects of Gentamicin","status":"TERMINATED","sponsor":"Singapore General Hospital","startDate":"2022-05-11","conditions":["Healthy Volunteers"],"enrollment":33,"completionDate":"2024-05-13"},{"nctId":"NCT03483363","phase":"PHASE4","title":"Topical Antibiotic Irrigation (Gentamicin) in Prophylaxis of Midfacial Fracture Surgical Wounds","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-10-09","conditions":["Surgical Site Infection"],"enrollment":39,"completionDate":"2022-01-02"},{"nctId":"NCT05143164","phase":"NA","title":"Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Singapore General Hospital","startDate":"2022-03-11","conditions":["Peritoneal Dialysis Catheter Exit Site Infection"],"enrollment":60,"completionDate":"2024-12-30"},{"nctId":"NCT05429671","phase":"PHASE3","title":"Antibiotic Loaded Cement After TKA","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","startDate":"2022-06-20","conditions":["Total Knee Arthoplasty"],"enrollment":50,"completionDate":"2023-11-30"},{"nctId":"NCT06042062","phase":"NA","title":"Clinical Evaluation of Infection Control to Knee Periprosthetic Joint Infection (PJI) -United Cellbrick Knee Spacer","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":["Knee; Infection, Joint"],"enrollment":10,"completionDate":"2025-07-31"},{"nctId":"NCT04709796","phase":"NA","title":"The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2021-03-03","conditions":["IVF","Embryo Loss","Miscarriage, Recurrent"],"enrollment":178,"completionDate":"2025-06-30"},{"nctId":"NCT06313281","phase":"NA","title":"Effectiveness of Preoperative Antiseptic Preparation in Transnasal Skull Base Surgery","status":"COMPLETED","sponsor":"King Saud University","startDate":"2019-02-01","conditions":["Meningitis and Sinusitis in Transnasal Surgery"],"enrollment":142,"completionDate":"2021-09-30"},{"nctId":"NCT06290882","phase":"NA","title":"Endoscopic Versus Robotic Myotomy for Treatment of Achalasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Germans Trias i Pujol Hospital","startDate":"2024-01-01","conditions":["Achalasia Cardia"],"enrollment":144,"completionDate":"2027-01-01"},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":["Staphylococcus Aureus"],"enrollment":265,"completionDate":"2023-06-30"},{"nctId":"NCT01785641","phase":"NA","title":"Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2012-12","conditions":["Peritonitis"],"enrollment":300,"completionDate":"2013-12"},{"nctId":"NCT05761405","phase":"EARLY_PHASE1","title":"Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-01-16","conditions":["Urinary Tract Infections","Urological System Complication of Procedure"],"enrollment":90,"completionDate":"2026-04-15"},{"nctId":"NCT06050785","phase":"","title":"Infection Rates Between Using of Vancomycin Versus Gentamycin in Primary ACLR","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-02-01","conditions":["Anterior Cruciate Ligament Injuries"],"enrollment":110,"completionDate":"2025-02-01"},{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":["Peritoneal Dialysis-associated Peritonitis"],"enrollment":46,"completionDate":"2026-10"},{"nctId":"NCT02865564","phase":"NA","title":"Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2016-11","conditions":["Gastrointestinal Diseases","Colic"],"enrollment":98,"completionDate":"2020-03"},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":["Bacterial Keratitis","Fungal Keratitis","Mixed Bacterial and Fungal Keratitis","Microbial Keratitis"],"enrollment":123,"completionDate":"2023-01-01"},{"nctId":"NCT06200402","phase":"NA","title":"Antibiotic-Loaded Cement Versus Non-Antibiotic-Loaded Cement in Hip Prosthesis Surgery for Proximal Femur Fractures","status":"UNKNOWN","sponsor":"Università Vita-Salute San Raffaele","startDate":"2023-07-01","conditions":["Proximal Femoral Fractures"],"enrollment":450,"completionDate":"2025-12-30"},{"nctId":"NCT03491540","phase":"PHASE3","title":"Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-03","conditions":["Rectal Cancer Surgery"],"enrollment":414,"completionDate":"2023-12-12"},{"nctId":"NCT06183606","phase":"","title":"Interest of High-dose Gentamicin Cement Associated With Clindamycin in Changes of Hip and Knee Prostheses","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-06-14","conditions":["Hip or Knee Replacement"],"enrollment":300,"completionDate":"2023-12"},{"nctId":"NCT03559400","phase":"NA","title":"Pilot RCT Local Gentamicin for Open Tibial Fractures in Tanzania","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-11-19","conditions":["Open Tibia Fracture"],"enrollment":100,"completionDate":"2021-09-15"},{"nctId":"NCT06168708","phase":"NA","title":"The Safety and Efficacy of Addition of Gentamicin on Irrigation Fluid in Prevention of Post-Transurethral Resection of the Prostate Infectious Complications.","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-12-07","conditions":["Post-TURP Infectious Complications"],"enrollment":220,"completionDate":"2024-07-07"},{"nctId":"NCT06117839","phase":"","title":"Rate of Infection After Using Antibiotic Loaded Cement and Regular Cement in Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":["Primary Osteoarthritis of Knee Nos"],"enrollment":42,"completionDate":"2025-01-01"},{"nctId":"NCT06143462","phase":"NA","title":"Vestibular Rehabilitation for Unsteadiness After Intratympanic Gentamicin in Patients With Meniere's Disease","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-01-01","conditions":["Vestibular Disorder"],"enrollment":48,"completionDate":"2024-12-31"},{"nctId":"NCT02848820","phase":"PHASE4","title":"Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children","status":"UNKNOWN","sponsor":"Ramon Gorter","startDate":"2016-12","conditions":["Appendicitis"],"enrollment":302,"completionDate":"2024-12"},{"nctId":"NCT02579161","phase":"PHASE3","title":"Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2014-09","conditions":["Kidney Stones"],"enrollment":98,"completionDate":"2018-12"},{"nctId":"NCT03945357","phase":"PHASE3","title":"Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2019-05-15","conditions":["Ventral Hernia Repair"],"enrollment":250,"completionDate":"2023-01-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Cream, Injection, Ointment","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"GENTAMICIN SULFATE"},{"form":"CREAM","route":"TOPICAL","productName":"Gentamicin Sulfate"},{"form":"CREAM","route":"TOPICAL","productName":"Gentamicin Sulfate Cream 0.1%"},{"form":"CREAM","route":"TOPICAL","productName":"Gentamicin Sulfate Cream USP, 0.1%"},{"form":"CREAM","route":"TOPICAL","productName":"AMOLG A"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"GENTAMICIN"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"GENTAMICIN SULFATE"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Gentamicin"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Gentamicin Sulfate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Gentamicin Sulfate in Sodium Chloride"},{"form":"OINTMENT","route":"OPHTHALMIC","productName":"Gentak"},{"form":"OINTMENT","route":"OPHTHALMIC","productName":"Gentamicin Sulfate"},{"form":"OINTMENT","route":"OPHTHALMIC","productName":"PRED-G"},{"form":"OINTMENT","route":"TOPICAL","productName":"Gentamicin Sulfate"},{"form":"OINTMENT","route":"TOPICAL","productName":"Gentamicin sulfate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179542","MMSL":"228599","NDDF":"002778","UNII":"T6Z9V48IKG","VUID":"4019765","CHEBI":"CHEBI:17833","VANDF":"4018210","INN_ID":"1617","RXNORM":"1596450","UMLSCUI":"C3854019","chemblId":"CHEMBL6067485","ChEMBL_ID":"CHEMBL3039597","KEGG_DRUG":"D01063","DRUGBANK_ID":"DB00798","PUBCHEM_CID":"3467","SNOMEDCT_US":"2249001","IUPHAR_LIGAND_ID":"2427","SECONDARY_CAS_RN":"1403-66-3","MESH_DESCRIPTOR_UI":"D005839"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1970-","companyName":"Schering","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.7 hours","clearance":"1.0 mL/min/kg","fractionUnbound":"1.0%","volumeOfDistribution":"0.33 L/kg"},"publicationCount":30865,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D06AX07","allCodes":["D06AX07","J01GB03","S01AA11","S02AA14","S03AA06"]},"biosimilarFilings":[],"originalDeveloper":"Schering","recentPublications":[{"date":"2026 Mar 28","pmid":"41905318","title":"Antibiotic use among beef cattle farmers in feedlots in Querétaro, Mexico.","journal":"Revista Argentina de microbiologia"},{"date":"2026 Mar 28","pmid":"41905081","title":"A baseline assessment of Enterococcus in low-contamination surface waters and their antibiotic resistance.","journal":"Marine pollution bulletin"},{"date":"2026 Mar 28","pmid":"41904538","title":"TNF-α impairs the stria vascularis by inducing pericyte apoptosis via the NF-κB pathway in gentamicin-induced hearing loss.","journal":"Journal of neuroinflammation"},{"date":"2026 Mar 29","pmid":"41904345","title":"UV-spectrometric study of antibiotic long-term release by different osteoplastic materials used in dentistry.","journal":"The Saudi dental journal"},{"date":"2026 Feb 9","pmid":"41903513","title":"Predictors, aetiology and outcome of early-onset neonatal bloodstream infection: a case-control study in a tertiary hospital in South Africa.","journal":"Journal of tropical pediatrics"}],"combinationProducts":[{"brandName":"PRED-G","ingredients":"gentamicin + prednisolone acetate"}],"companionDiagnostics":[],"genericManufacturers":36,"_genericFilersChecked":true,"genericManufacturerList":["Abbott","Alcon Pharms Ltd","Allergan","Alpharma Us Pharms","B Braun","Bausch And Lomb","Baxter Hlthcare","Bristol","Cosette","Encube","Epic Pharma Llc","Eugia Pharma","Fera Pharms Llc","Fougera Pharms Inc","Fresenius Kabi Usa","Hikma","Hospira","Intl Medication","Kalapharm","King Pharms","Novartis","Paco","Padagis Us","Pharm Spec","Pharmacia And Upjohn","Pharmaderm","Pharmafair","Pharmobedient","Sandoz","Schering","Sciegen Pharms","Solopak","Sun Pharma Canada","Teva Parenteral","Watson Labs","Wyeth Ayerst"],"status":"approved","companyName":"Schering","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1970","aiSummary":"","enrichmentLevel":4,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1970-06-19T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-10-04T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"ANDA062420"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-04-29T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA064054"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-04-29T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA064056"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-06-27T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"ANDA064048"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-11T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"ANDA062373"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"375.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:15.673146+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}